CN115335527A - 产生真核生物可翻译mRNA并将其传递给真核生物的微生物系统 - Google Patents

产生真核生物可翻译mRNA并将其传递给真核生物的微生物系统 Download PDF

Info

Publication number
CN115335527A
CN115335527A CN202180008864.6A CN202180008864A CN115335527A CN 115335527 A CN115335527 A CN 115335527A CN 202180008864 A CN202180008864 A CN 202180008864A CN 115335527 A CN115335527 A CN 115335527A
Authority
CN
China
Prior art keywords
eukaryotic
mrna
translatable
translatable mrna
ires
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008864.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·林克
A·B·威廉姆斯
D·莫拉
M·考克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siweike Biotechnology Co ltd
Original Assignee
Siweike Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siweike Biotechnology Co ltd filed Critical Siweike Biotechnology Co ltd
Publication of CN115335527A publication Critical patent/CN115335527A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180008864.6A 2020-01-11 2021-01-11 产生真核生物可翻译mRNA并将其传递给真核生物的微生物系统 Pending CN115335527A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062959976P 2020-01-11 2020-01-11
US62/959,976 2020-01-11
US202063118593P 2020-11-25 2020-11-25
US63/118,593 2020-11-25
PCT/US2021/012992 WO2021142458A1 (en) 2020-01-11 2021-01-11 A microbial system for production and delivery of eukaryote-translatable mrna to eukarya

Publications (1)

Publication Number Publication Date
CN115335527A true CN115335527A (zh) 2022-11-11

Family

ID=76788329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008864.6A Pending CN115335527A (zh) 2020-01-11 2021-01-11 产生真核生物可翻译mRNA并将其传递给真核生物的微生物系统

Country Status (8)

Country Link
US (1) US20210222178A1 (https=)
EP (1) EP4087934A4 (https=)
JP (1) JP2023509964A (https=)
KR (1) KR20220150276A (https=)
CN (1) CN115335527A (https=)
AU (1) AU2021206307A1 (https=)
CA (1) CA3164395A1 (https=)
WO (1) WO2021142458A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
IL300447A (en) * 2020-08-12 2023-04-01 Actym Therapeutics Inc Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
AU2022286964A1 (en) * 2021-06-02 2024-01-18 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells
CN114507691A (zh) * 2022-03-02 2022-05-17 深圳市瑞吉生物科技有限公司 一种用于制备环状rna的载体及其应用
CN114622020B (zh) * 2022-03-30 2022-09-27 华南农业大学 一种与鸡生长性状相关的klhl31基因分子标记及应用
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
CN120400199A (zh) * 2024-01-31 2025-08-01 上海缮维特生物技术有限公司 一种真核表达载体、包含其的细菌及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500419B1 (en) * 1997-10-07 2002-12-31 University Of Maryland Biotechnology Institute Method for introducing and expressing RNA in animal cells
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
US20140147454A1 (en) * 2012-11-26 2014-05-29 Moderna Therapeutics, Inc. Terminally modified rna
WO2014186334A1 (en) * 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
WO2018187381A2 (en) * 2017-04-03 2018-10-11 Sivec Biotechnologies, Llc A transkingdom platform for therapeutic nucleic acid delivery
WO2020010344A1 (en) * 2018-07-04 2020-01-09 Pebble Labs Usa, Inc. System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500419B1 (en) * 1997-10-07 2002-12-31 University Of Maryland Biotechnology Institute Method for introducing and expressing RNA in animal cells
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
US20140147454A1 (en) * 2012-11-26 2014-05-29 Moderna Therapeutics, Inc. Terminally modified rna
WO2014186334A1 (en) * 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
JP2016521133A (ja) * 2013-05-15 2016-07-21 クルーゼ，ロバート 環状ｒｎａの細胞内翻訳
WO2018187381A2 (en) * 2017-04-03 2018-10-11 Sivec Biotechnologies, Llc A transkingdom platform for therapeutic nucleic acid delivery
WO2020010344A1 (en) * 2018-07-04 2020-01-09 Pebble Labs Usa, Inc. System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUO H等: "Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi", GENE THER, vol. 18, no. 1, 2 September 2010 (2010-09-02), XP037773869, DOI: 10.1038/gt.2010.112 *
ROSTAIN W等: "Engineering a Circular Riboregulator in Escherichia coli", BIODES RES, vol. 2020, 14 September 2020 (2020-09-14), XP093123527, DOI: 10.34133/2020/1916789 *
SCHOEN C等: "Bacterial delivery of functional messenger RNA to mammalian cells", CELL MICROBIOL, vol. 7, no. 5, 31 May 2005 (2005-05-31), XP055672606, DOI: 10.1111/j.1462-5822.2005.00507.x *
UMEKAGE S等: "In vivo circular RNA production using a constitutive promoter for high-level expression", J BIOSCI BIOENG, vol. 108, no. 4, 31 October 2009 (2009-10-31), XP026564195, DOI: 10.1016/j.jbiosc.2009.04.011 *

Also Published As

Publication number Publication date
WO2021142458A1 (en) 2021-07-15
EP4087934A4 (en) 2024-03-13
KR20220150276A (ko) 2022-11-10
JP2023509964A (ja) 2023-03-10
EP4087934A1 (en) 2022-11-16
US20210222178A1 (en) 2021-07-22
CA3164395A1 (en) 2021-07-15
AU2021206307A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
CN115335527A (zh) 产生真核生物可翻译mRNA并将其传递给真核生物的微生物系统
US20240229109A1 (en) Methods for identification and ratio determination of rna species in multivalent rna compositions
US20230061936A1 (en) Methods of dosing circular polyribonucleotides
CN104220599A (zh) 人工核酸分子
CN115151277A (zh) 负载核酸的红细胞细胞外囊泡
AU2018391796B2 (en) Click-modified mRNA,
CN114788876B (zh) 治疗糖尿病的mRNA药物制剂及其制备方法与应用
CN115768487A (zh) 用于面肩肱型肌营养不良症的crispr抑制
US9555127B2 (en) Systems and methods for diminishing cell growth and inducing selective killing of target cells
WO2022036618A1 (zh) 携带细胞因子或其多核苷酸的细菌靶向载体及其在肿瘤治疗中的应用
IL298978A (en) Tandem anellovirus constructs
US20240123034A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
KR20260022409A (ko) 발현 조절이 가능한 엔지니어링된 rna 분자
CN117965584A (zh) 一种编码IL-2融合蛋白的mRNA及其药物制剂与应用
EP3502258A1 (en) Click-modified in vitro transcribed mrna for gene expression
CN120051568A (zh) 具有改善的活性的经修饰转运rna
CN120168624B (zh) 一种伪狂犬免疫原组合物及其用途
WO2024139837A1 (en) Recombinant nucleic acids, kits comprising the same, and uses thereof in treating coronavirus infection
EP4495243A1 (en) Novel method for producing exosome containing target nucleic acid and serving as nucleic acid medicine
WO2025247180A1 (zh) 用于制备含较少非目的序列的环状rna的载体和方法
US20120114710A1 (en) Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
HK40114401A (zh) 用於基因组编辑的多核苷酸、组合物和方法
KR20250047640A (ko) 비천연 3'비번역 영역 및 그의 용도
CN118660960A (zh) 用于基因组编辑的多核苷酸、组合物和方法
CA3249795A1 (en) ARNT UNIVERSAL SUPPRESSANTS AND THEIR USES

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination